Meeder Asset Management Inc Fate Therapeutics Inc Transaction History

Meeder Asset Management Inc

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$47.84 - $64.34 $141,080 - $189,738	-2,949 Closed	0 $0
Q3 2021 Nov 08, 2021	SELL	$59.27 - $95.73 $16,536 - $26,708	-279 Reduced 8.64%	2,949 $175,000
Q2 2021 Aug 09, 2021	BUY	$67.25 - $92.52 $22,192 - $30,531	330 Added 11.39%	3,228 $280,000
Q1 2021 Apr 28, 2021	BUY	$72.16 - $117.4 $209,119 - $340,225	2,898 New	2,898 $239,000
Q4 2020 Feb 09, 2021	SELL	$38.09 - $100.95 $81,245 - $215,326	-2,133 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$30.41 - $40.5 $94,301 - $125,590	-3,101 Reduced 59.25%	2,133 $84,000
Q2 2020 Aug 11, 2020	BUY	$20.21 - $35.23 $13,379 - $23,322	662 Added 14.48%	5,234 $180,000
Q1 2020 May 15, 2020	BUY	$17.28 - $31.88 $43,943 - $81,070	2,543 Added 125.33%	4,572 $101,000
Q4 2019 Feb 13, 2020	BUY	$13.39 - $20.73 $8,569 - $13,267	640 Added 46.08%	2,029 $39,000
Q3 2019 Oct 17, 2019	SELL	$15.47 - $22.5 $134,882 - $196,177	-8,719 Reduced 86.26%	1,389 $21,000
Q2 2019 Aug 05, 2019	BUY	$15.61 - $20.44 $113,672 - $148,844	7,282 Added 257.68%	10,108 $205,000
Q1 2019 Apr 16, 2019	BUY	$13.15 - $18.71 $26,497 - $37,700	2,015 Added 248.46%	2,826 $50,000
Q4 2018 Jan 17, 2019	BUY	$11.48 - $16.98 $2,043 - $3,022	178 Added 28.12%	811 $10,000
Q3 2018 Nov 02, 2018	SELL	$8.75 - $16.29 $17,088 - $31,814	-1,953 Reduced 75.52%	633 $0
Q2 2018 Jul 24, 2018	BUY	$9.16 - $13.48 $13,300 - $19,572	1,452 Added 128.04%	2,586 $0
Q1 2018 May 03, 2018	BUY	$6.3 - $13.77 $5,777 - $12,627	917 Added 422.58%	1,134 $12,000
Q4 2017 Feb 02, 2018	BUY	$3.94 - $6.64 $854 - $1,440	217	217 $1,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.